---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-286825"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2026-06-29T11:15:14+00:00"
generated_at: "2026-06-29T11:20:14.178513+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO doses first patient in Phase IIb/III DR trial; earns $100M milestone from AbbVie

## Summary
- First patient dosed in Phase IIb/III NAAVIGATE trial of sura-vec for diabetic retinopathy using suprachoroidal delivery.
- Triggered $100M milestone payment from AbbVie, expected in July 2026.
- Phase IIb portion to enroll ~135 patients in U.S.; primary endpoint is ≥2-step DRSS improvement at one year.
- To present 2.5-year ALTITUDE and 5-year subretinal data at ASRS July 2026.
- Topline data from ATMOSPHERE and ASCENT pivotal trials expected Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-286825
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2026-06-29T11:15:14+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000119312526286825/0001193125-26-286825-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000119312526286825/rgnx-20260623.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-286825
- JSON: https://secwatch.observer/filing/0001193125-26-286825.json
- Plain text: https://secwatch.observer/filing/0001193125-26-286825.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.